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Abstract
Objectives. Uterine carcinosarcomas are uncommon, highly aggressive neoplasms that frequently recur after surgical treatment and
adjuvant chemo-radiotherapy. Patients with recurrent disease respond poorly to salvage chemotherapy and irradiation. New therapeutic
options are required for patients with metastatic disease. Clinical evidences showing the effect of a tyrosine kinase inhibitor, STI571, in c-
KIT-positive gastrointestinal tumors, the role of COX-inhibitors chemotherapy-associated in colorectal cancer patients and the successful
therapeutic possibility of anti-HER2 therapy in metastatic breast carcinoma, have encouraged us to study the expression of c-KIT, COX-2 and
HER-2/neu in uterine carcinosarcomas.
Methods. We analyzed the expression of COX-2, c-KIT and HER-2/neu in 24 uterine carcinosarcomas and their correlation with clinical
outcome. Disease-free interval and actuarial survival rates were the end points of the study.
Results. High staining intensity for COX-2 was observed in 8 cases (33.3%). C-KITwas expressed in 4 cases (16.7%) and HER-2/neu in 7
cases (29.2%). Patients with COX-2-positive tumors had a significantly poorer disease-free interval and survival (P = 0.01 and P = 0.05,
respectively). All patients with c-KIT-positive tumors had early stage disease. In spite of this, their survival was not significantly better than
that of c-KIT-negative cases. HER-2/neu expression did not show any correlation with clinical outcome.
Conclusion. c-KIT, COX-2, and HER-2/neu were expressed in different proportions of uterine carcinosarcomas. COX-2 expression was a
strong indicator of unfavorable prognosis. These results warrant further study to evaluate the possible role of a new molecularly targeted
cancer therapy with COX-2 inhibitors in patients with uterine carcinosarcomas. The role of c-KIT expression and consequently the
hypothetical use of STI571 should be tested in a larger series.
D 2004 Elsevier Inc. All rights reserved.
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Introduction
Uterine carcinosarcomas are uncommon malignancies
composed of carcinomatous and sarcomatous elements, in
which the sarcomatous component may be either homolo-
gous or heterologous [1]. These highly aggressive tumors
usually occur in advanced-age women [2]. Although the
presence of the heterologous sarcomatous component was
previously considered as an indicator of poor prognosis [3],
currently tumor stage appears the only independent prog-
nostic indicator of survival for these malignancies [2].
The 5-year survival rates of women with uterine
carcinosarcomas is reported to range between 18% and
39% [4].
Total abdominal hysterectomy with bilateral salpingo-
oophorectomy and pelvic lymph node dissection is the
standard treatment. Adjuvant therapies are generally recom-
mended in cases with extra-uterine spread. The chemo-
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therapeutic regimen for uterine carcinosarcomas includes
the same drugs also used for uterine malignant stromal
tumors such as leiomyosarcomas or undifferentiated sarco-
mas [5]. However, the chemotherapies currently proposed
are inadequate to control metastatic and unresectable
diseases [6].
Although evidence from the literature of the last years is
conflicting, recent studies have observed that the behavior
of uterine carcinosarcomas depends more on the character-
istics of the epithelial component than on the stromal
component [7]. In addition, an in vitro study suggests that
both the epithelial and the mesenchymal components of
uterine carcinosarcomas derive from a common stem cell of
epithelial origin [8]. A recent study showing the sensitivity
of carcinosarcomas to cisplatin supports the hypothesis that
these tumors could be high grade carcinomas with meta-
plastic sarcomatous elements [9].
The enzyme cyclooxygenase (COX) is responsible for
the conversion of arachidonic acid to prostaglandins. The
cyclooxigenase-1 (COX-1) is constitutively expressed in a
wide range of tissue, while the cyclooxigenase-2 (COX-2) is
inducible by pro-inflammatory cytokines and growth factors
[10]. COX-2, which has a role in inflammatory processes
and in control of cell growth, has also been associated with
carcinogenesis [11]. Research over the last decade has
established that nonsteroidal anti-inflammatory drugs are
effective in both cancer prevention and as adjuvant therapy
in the treatment of colorectal cancer [12].
The 145-kDa KIT tyrosine kinase transmembrane recep-
tor is involved in cell signal transduction. The physiologic
ligand is the cytokine stem cell factor (SFC), also called
mast cell growth factor or Steel factor [13]. Gastrointestinal
stromal tumor (GIST) cells express a growth factor receptor
with tyrosine kinase activity termed c-kit [14]. Mutation of
c-kit, detectable in most GISTs, cause uncontrolled cell
proliferation [15]. According to initial clinical studies, the
majority of GISTs respond to therapy with a competitive
inhibitor of tyrosine kinases, such as STI571 [16].
Human epidermal growth factor receptor (HER-2/neu) is
overexpressed in 25–30% of breast cancers, increasing the
aggressiveness of the tumor [17]. HER-2/neu has a direct
role in the pathogenesis of breast carcinomas [18]. There is
evidence to encourage the use of chemotherapy plus a
monoclonal antibody against HER-2/neu for metastatic
breast cancer that overexpresses HER-2/neu [19].
Altogether, these evidences showing the effect of a
tyrosine kinase inhibitor, STI571, in c-KIT-positive gastro-
intestinal tumors, the role of COX-inhibitors chemotherapy-
associated in colorectal cancer patients and the successful
therapeutic possibility of anti-HER2 therapy in metastatic
breast carcinoma, have encouraged us to study the
expression of c-KIT, COX-2 and HER-2/neu in uterine
carcinosarcomas.
The aim of this study was to investigate the expression of
COX-2, c-KIT and HER-2/neu as prognostic factors in a
series of uterine carcinosarcoma patients and to evaluate the
possible role of these markers in the selection of patients as




The files of the Department of Human Pathology and
Oncology of the University of Florence were searched from
1980 to 1999 for the diagnosis of uterine carcinosarcomas.
The specimens come from 24 patients who had undergone
surgery at the Department of Gynecology, Perinatology and
Reproductive Medicine of the University of Florence. The
mean age of the patients was 68.1 (F10.1) years of age
(range, 41–86 years). All patients were staged retrospec-
tively, according to a modified staging system of the
International Federation of Gynecology and Obstetrics
(FIGO) for corpus uteri carcinomas and mixed mesodermal
tumors [20]. We derived staging information from operative
notes and pathology reports. Follow-up information for all
patients were available from the gynecologic oncologic
database of the Department of Gynecology.
All microscopic slides were reviewed to confirm the
histologic diagnosis, without knowledge of the clinical
outcome. The diagnosis of uterine carcinosarcoma was
based on previously published criteria [1].
Treatment and follow-up
The patients underwent total abdominal hysterectomy,
bilateral salpingo-oophorectomy, and debulking in cases
with pelvic and/or abdominal spread. Peritoneal cytology
and peritoneal biopsies were performed to rule out extra-
uterine disease when indicated.
After surgery, 6 patients (25%) received adjuvant
chemotherapy. Because the study encompasses a relatively
large period of time, different drug regimens were used,
including cisplatin, cyclophosphamide and epirubicin in
more recent years. The chemotherapy regimen more
frequently used included: cisplatin (60 mg/m2 body-surface
area) in combination with cyclophosphamide (600 mg/m2
body-surface area) and epirubicin (60 mg/m2 body-surface
area) every 21 days for six cycles. Whole pelvis adjuvant
external irradiation (56 Gy) was given in 3 patients (12.5%).
All patients, at the time of diagnosis, were free of distant
metastases. During the follow-up period, patients were seen
regularly every 4 months in the first 2 years, every 6 months
until the fifth year and once a year thereafter. Each time, a
pelvic examination and a Pap smear from the vaginal vault
were done. An abdomino-pelvic ultrasound scan was
performed every 6 months, chest X-ray and CT scan were
performed every year. Local recurrences, distant metastases
and deaths were noted. The median follow-up time for the
surviving patients was 66 months (range 23–114 months).
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Tissue specimens and immunohistochemistry
The specimens were obtained by surgical resection in
all cases and fixed in 10% formalin before being
processed in paraffin. Hematoxylin–eosin stained sections
from each histological specimen were reviewed by two
pathologists to confirm the histological diagnosis. In
addition, for each case, presence of tumor necrosis, depth
of myometrial invasion, vessel infiltration, pattern of
tumor growth and presence of heterologous component
were evaluated. We considered tumor necrosis present
when coagulative tumor cell necrosis was found [21].
Vessel infiltration was considered present when embolic
tumor cells were documented in blood and/or lymphatic
vessels of the tumor area. No quantitative criteria was
adopted. The infiltrative pattern of growth was charac-
terized by poorly demarcated margins, with glandular and
mesenchymal elements irregularly scattered through the
myometrium.
A representative section from each lesion was selected
for immunohistochemical analysis. All sections were
deparaffinized in Bio-Clear (Bio-Optica, Mi, Italy) and
hydrated with grade ethanol concentration and finally with
distilled water.
Antigen retrieval was routinely performed by microwave
pretreatment (Microwave MicroMed T/T Mega, Milestone,
Bg, Italy) in TEC buffer (TRIS-EDTA-Citrate), pH 7.8, for
30 min. We evaluated the immunohistochemical staining of
uterine carcinosarcomas as follows.
Concerning COX-2, after blocking nonspecific antigen
with normal horse serum (UltraVision, Lab-Vision, Fre-
mont, CA), the sections were incubated overnight at 48C
with primary goat polyclonal anti-Cox-2 (sc-1745, Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) at 1:50
dilution. Staining was achieved using a biotin-conjugated
anti-goat secondary antibody (Goat immunoglobulins,
DAKO, A/S Denmark) and streptavidin–peroxidase
(UltraVision). The bound antibodies were visualized using
3.3V diaminobenzidine (BioGenex, San Ramon, CA) as
chromogen. Nuclei were slightly counterstained with
Mayer’s hematoxylin. A section containing a COX-2
strongly positive colonic carcinoma, served as the positive
control with each run. A negative control sample was
included with each run by omitting the primary antibodies
and yielded no signal.
Concerning c-KIT, we used a commercial rabbit
polyclonal anti-c-KIT (Ventana Medical Systems, Tucson,
AZ) raised against a peptide sequence mapping with the
carboxy terminal domain of c-Kit with molecular weight of
145 kDa of human origin. All tissue sections were then
placed on the Ventana NexES automated stainer using
iVIEW DAB Detection Kit as a revelation system. The
primary antibody to c-KIT was placed on the slides and
incubated for 32 min according to the protocol suggested
by Immunostainer Ventana NexES. When the staining run
was complete, the tissue sections were removed from the
stainer, counterstained with hematoxylin, dehydrated and
mounted with Permount. A section containing a c-KIT
strongly positive GIST served as the positive external
control with each run. Mast cells within the tumor served
as positive internal control. Each tumor was also stained
with Giemsa to identify mast cells for comparison with the
c-KIT results. A negative control sample was included
with each run by omitting the primary antibodies and
yielded no signal.
Concerning HER-2/neu, the samples were analyzed
using the HercepTest TM Kit (DakoCytomation, Glostrup,
Denmark A/S). All sections were subjected to an antigen
retrieval technique by immersing the slides in thermostate
bath at 978C containing preheated Dako Epitope Retrieval
Solution (0.1 mol/L citrate buffer, pH 6.0) for 40 min
followed by cooling for 20 min r.t. After incubation with
the polyclonal antibody anti-human HER-2 protein for 30
min, a ready-to-use Visualization Reagent based on
dextran technology (dextran polymer conjugated with
horseradish peroxidase and goat anti-rabbit immunoglobu-
lins) was applied for 30 min. Bound antibody was detected
using 3.3V diaminobenzidine as chromogen. The sections
were weakly counterstained with the Mayer’s hematoxylin.
In each staining run, a control slide containing three
formalin-fixed, paraffin-embedded human breast cancer
cell lines with staining intensity scores of 0, 1+ and 3+
was added. A negative control sample was included with
each run by omitting the primary antibodies and yielded no
signal.
Evaluation of immunohistochemical staining
Positive c-KIT stains appeared as cytoplasmic and/or
membranous stains. The percentage of positive cells, and
the degree and cellular distribution of the staining were
scored. Only cases showing at least 20% moderate to strong
membranous and/or cytoplasmic positivity were scored as
positive, as previously described [22]. We evaluated both
epithelial and mesenchymal component. No background or
nonspecific staining of endometrial tissue and adjacent
myometrial parenchyma was encountered, other than
positivity in mast cells as expected.
The tumor sections showing brown staining of the
antibody specific COX-2 of cytoplasm were scored as
positive. The proportion of immunostained cells was scored
at low magnification (5! objective lens) by evaluating the
entire tumor area. When the tumor area with positive
immunostaining was N10% of the total tumor area, the case
was scored as positive. The intensity of staining was also
evaluated subjectively using a range from 0 (none) to 1
(faint) to 2 (strong). Cases in which the intensity of staining
was scored b2 were considered negative, as previously
described [23]. We evaluated both epithelial and mesen-
chymal component.
HER-2/neu was evaluated as positive only when in the
tumor sections the membranous staining was scored, with
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cytoplasmic staining being ignored. A four-point scale was
used: 0 if there was no membranous staining; 1 if there was
weak membrane staining in at least 10% of cells; 2 if there
was moderate membrane staining in at least 10% of cells; 3
if there was strong membrane staining in at least 10% of
cells. We have considered as positive only the cases that had
weak-to-moderate staining of the entire tumor-cell mem-
brane for HER-2/neu (referred to as a score of 2+) or more
than moderate staining (referred to as a score of 3+) in more
than 10% of tumor cells, as previously described [19]. We
evaluated both epithelial and mesenchymal component.
To assess the interobserver variability in the evaluation of
immunohistochemical stainings, the evaluations of one
author (M.R.R.) were compared with those of one of the
other authors (G.L.T.). Initially, the slides were evaluated
independently, and those graded diversely were subse-
quently reevaluated by the two authors together and
agreement was found. The immunohistochemical analysis
was evaluated in a blinded fashion with regard to the clinical
data.
Statistical analysis
Data analysis was performed using the SPSS Version
8.0 (Chicago, IL) statistical package. Frequency data were
evaluated by the Fisher’s exact test or the Chi-square test.
Disease-free interval and cause-specific survival rates
were calculated according to the Kaplan–Meier method
and differences were evaluated using the log rank test. A
P value V0.05 was considered to be statistically
significant.
Results
Areas of tumor necrosis were observed in 11 cases
(45.8%). Ten cases (41.7%) showed vessels infiltration.
Myometrial invasion was N50% in 11 cases (45.8%). In 14
cases (58.3%), the tumor showed an infiltrating pattern of
growth. An heterologous component was observed in 10
patients (41.7%), in particular, 3 cases (12.5%) had
rhabdomyosarcomatous differentiation, 5 cases (20.8%)
Fig. 1. Kaplan–Meier estimates for disease-free survival (A) and disease-
specific survival (B) according to FIGO stage (I–II) vs. (III–IV) in 24
patients with uterine carcinosarcoma.
Fig. 2. COX-2-positive cytoplasmic immunostaining in the epithelial (A)
and in the mesenchymal component (B) of uterine carcinosarcoma. Original
magnification !200.
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had chondrosarcomatous differentiation, and 2 cases (8.3%)
had osteosarcomatous differentiation.
Distribution by FIGO stage was as follows: stage I, 17
patients (70.8%); stage II, 1 patient (4.1%); stage III, 4
patients (16.6%); stage IV, 2 patients (8.3%). For the
purpose of survival evaluation, patients with disease limited
to the uterus (stage I–II) were compared with those with
extrauterine tumor spread (stage III–IV).
During the follow-up period, 15 patients (62.5%)
recurred and 16 patients (66.7%) died of disease.
Among the conventional clinico-pathological parameters
analyzed, only tumor stage (I–II vs. III–IV) was a significant
prognostic factor for disease-free interval and survival (P =
0.01 and P = 0.02, respectively) (Fig. 1).
COX-2, c-KIT and HER-2/neu expression
Positive staining for COX-2 was observed in 8 cases
(33.3%). In the cases with positive immunostaining, the
epithelial and mesenchymal components were stained,
although in the mesenchymal component the percentage
of stained cells was lower, (e.g., epithelial component 50%
of the cells stained; mesenchymal component 30% of the
stained cells) (Fig. 2). Distribution of COX-2 positivity was
not significantly different according to FIGO stage (Fish-
er’s exact test), with COX-2 positive tumors being 5/18 in
stage I–II disease and 3/6 in stage III–IV disease,
respectively. Conversely, COX-2 positivity was signifi-
cantly more frequent in tumors showing vessels infiltration
(P = 0.002, Fisher’s exact test) (Table 1). Patients with
COX-2 expression showed significantly poorer disease-free
interval and survival (P = 0.01 and P = 0.05, respectively)
(Fig. 3).
c-KIT expression was observed In 4 cases (16.7%).
Positive cases displayed immunostaining in both glandular
and mesenchymal component (Fig. 4). The ratio of
epithelial stained cells was slightly higher than in the
mesenchymal component. Also, the intensity of immunos-
taining tended to be stronger in the epithelial component.
All the 4 patients with distinct c-KIT immunoreactivity had
early stage disease (FIGO I–II) (difference not significant,
Fisher’s exact test). These four patients fared better than
those with c-Kit-negative tumors, but the difference was not
statistically significant (Fig. 5).
HER-2/neu expression was observed in 7 cases (29.2%).
Again, the epithelial and mesenchymal component were
both stained in positive cases, with a tendency towards more
intense immunostaining in glandular pattern (score 3+) than
in the mesenchymal areas (score 2+) (Fig. 6). Of the seven
patients with distinct HER-2/neu positive staining, six had
Table 1
Distribution of COX-2, c-KIT and HER-2/neu positivity, according to
clinico-pathological factors in 24 patients with uterine carcinosarcoma
Characteristic Total COX-2+ c-KIT+ HER-2/neu+
No. (%) No. (%) No. (%)
Necrosis
Present 11 4 (36.3) 1 (9.0) 4 (36.3)
Absent 13 4 (30.7) 3 (23.0) 3 (23.0)
Vessels infiltration
Present 10 7 (70.0)* 1 (10.0) 4 (40.0)
Absent 14 1 (7.1)* 3 (21.4) 3 (21.4)
Myometrial invasion
N50% 11 6 (54.5) 1 (9.0) 2 (18.0)
V50% 13 2 (15.3) 3 (23.0) 5 (38.4)
Pattern of growth
Infiltrating 14 5 (35.7) 1 (7.1) 6 (42.8)
Pushing 10 3 (30.0) 3 (30.0) 1 (10.0)
Mesenchymal component
Heterologous 10 3 (30.0) 1 (10.0) 5 (50.0)
Homologous 14 5 (35.7) 3 (21.4) 2 (14.2)
Age
b60 years 4 1 (25.0) – (–) 1 (25.0)
z60 years 20 7 (35.0) 4 (20.0) 6 (30.0)
FIGO stage
I–II 18 5 (27.7) 4 (22.2) 6 (33.3)
III–IV 6 3 (50.0) – (–) 1 (16.6)
* P = 0.002, Fisher’s exact test.
Fig. 3. Kaplan–Meier estimates for disease-free survival (A) and disease-
specific survival (B) according to COX-2 expression in 24 patients with
uterine carcinosarcoma.
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early stage disease and one had advanced stage disease
(FIGO III–IV). The distribution of HER-2/neu positivity
according to FIGO stage was not statistically significant
(Fisher’s exact test).
Disease free interval and survival rates were not
significantly different according to HER-2/neu expression
(Fig. 7).
The correlations between clinico-pathological factors and
immunohistochemical data concerning COX-2, c-KIT, and
HER-2/neu expression are summarized in Table 1.
Discussion
This study tested the expression of potential markers for
innovative molecularly targeted therapies such as COX-2,
c-KIT and HER-2/neu in uterine carcinosarcomas. We
found that COX-2, c-KIT and HER-2/neu are expressed in
different proportions of patients with uterine carcinosarco-
mas. Tumor stage was the only traditional clinical-
pathological factor with prognostic value in this series of
24 uterine carcinosarcomas, in agreement with previously
published data [2].
COX-2 overexpression was noted in one third of the
cases and was significantly correlated with vessels infiltra-
tion by tumor cells. Patients with COX-2 overexpression
were found in both early and advanced stage disease. These
patients fared significantly worse than those without COX-2
overexpression (Fig. 3). To the best of our knowledge, this
is the first study that analyzes the prognostic role of COX-2
expression in uterine carcinosarcomas. There is only one
previous study by Matsumoto et al. [24], which tested COX-
2 expression in eight uterine carcinosarcomas, reporting a
positive immunostaining in 88.9% of the cases, but no
information nor on vessels infiltration neither on the clinical
outcome was given. The different cutoff value for COX-2
positivity used by them can explain the higher positivity rate
in that study. Overexpression of COX-2 has been reported in
a number of other malignancies, including endometrial [25],
ovarian [26] and cervical carcinomas [27]. In agreement
with these previous studies on different gynecological
tumors, we documented a more aggressive clinical behavior
for the COX-2-positive carcinosarcomas, independently of
tumor stage. Ferrandina et al. reported that in cervical [27]
and ovarian carcinomas [23], COX-2 overexpression
correlates with unfavorable clinical outcome and with
platinum-based chemotherapy resistance. Unfortunately,
only a minority of the patients (25%) in the current study
Fig. 4. c-KIT-positive cytoplasmic immunostaining in the epithelial (A) and
in the mesenchymal component (B) of uterine carcinosarcoma. Original
magnification !200.
Fig. 5. Kaplan–Meier estimates for disease-free survival (A) and disease-
specific survival (B) according to c-KIT expression in 24 patients with
uterine carcinosarcoma.
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received adjuvant chemotherapy and among them only three
had regimens including platinum. This prevents us to test
any relationship between COX-2 overexpression and
platinum chemosensitivity in the current series.
At present, the use of platinum-based chemotherapy is
under evaluation also in patients with uterine carcinosar-
coma [28]. Therefore, information on platinum resistance
could be clinically useful in these tumors. Furthermore, it
has been shown that molecularly targeted therapies, such as
COX-2 inhibitors, are indicated for colorectal cancer
patients with COX-2 overexpression, in combination with
traditional chemotherapy [29]. It has been suggested also
that selective COX-2 inhibitors may have a role in the
treatment of subgroup of patients with cervical and ovarian
carcinomas [23,27]. In fact, COX-2 inhibitors have been
demonstrated to enhance the cytotoxicity in vitro of several
chemotherapeutic agents, including platinum [30]. Simi-
larly, we could hypothesize that nonsteroidal anti-inflam-
matory drugs may have synergistic effects with platinum-
based chemotherapy also in uterine carcinosarcoma patients
who express COX-2. Our data, demonstrating overexpres-
sion of COX-2 in 33% of uterine carcinosarcomas, provide
a rationale basis for further studies, to test the possible role
of COX-2 inhibitors in the treatment of these aggressive
malignancies.
Concerning c-KIT expression, we found positive immu-
nostaining in 16.7% of the patients. All of them had early
stage disease and did not display a significant correlation
with clinical outcome (Fig. 5). However, it should be noted
that c-KIT expression in GISTs is associated with unfavor-
able prognosis. Thus, this might explain why the outcome of
the c-KIT-positive cases in this series was poorer than
expected. In fact, the c-KIT-positive (early stage) cases did
not fare significantly better of the c-KIT-negative group,
which also included advanced stage cases. The finding of a
relatively low percentage of-positive c-KIT immunostaining
in the current series is in agreement with the study of Klein
and Kurman [31], who reported that c-KIT expression was
rare in uterine carcinosarcoma (0 of 6) and endometrial
stromal sarcoma (1 of 12). Conversely, Winter et al. [32]
and Sawada et al. [33] reported higher incidences of c-KIT
positivity among 21 and 16 patients, respectively. The low
Fig. 6. HER-2/neu-positive membranous immunostaining in the epithelial
(score 3+) (A) and in the mesenchymal component (B) of uterine
carcinosarcoma (score 2+). Original magnification !200.
Fig. 7. Kaplan–Meier estimates for disease-free survival (A) and disease-
specific survival (B) according to HER-2/neu expression in 24 patients with
uterine carcinosarcoma.
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number of cases in these series and differences in the type of
c-KIT antibody used may account for this variability. In the
current study, the low number of patients with c-KIT-
positive tumors prevents any definitive statement concern-
ing the prognostic significance of c-KIT expression in
uterine carcinosarcomas. It is known that STI571, a
competitive inhibitor of tyrosine kinases, has been shown
to be of value in the treatment of hematologic malignances
[34] and in metastatic GISTs that express immunohistoche-
micaly the c-KIT. Among GIST patients, the cases that
respond better to STI571 are those with a mutation in exon
11 of the c-kit gene [35]. We provided further evidence that
uterine carcinosarcomas express c-KIT. However, the
possibility to use this marker to select patients for innovative
targeted therapies using STI571 need to be demonstrated.
The immunohistochemical overexpression of c-KIT has
been reported also in other malignances such as small cell
lung cancer [36] and uterine leiomyosarcomas [37]. Our
previous study on c-KIT expression in uterine leiomyosar-
comas failed to detect any mutation in exon 11 of the c-kit
gene [37]. Therefore, the site of c-kit gene mutation and
whether uterine carcinosarcoma patients may respond to
KIT inhibition remain to be established and these are
questions for future studies.
Concerning HER-2/neu expression, we found a positive
immunostaining in approximately one third of our series.
Most of the HER-2/neu-positive tumors were found among
early stage disease patients, but this difference was not
significant. No differences in disease-free and disease-
specific survival rates were observed according to HER-2/
neu expression (Fig. 7). To our knowledge, the current study
is the first to evaluate the prognostic role of HER-2/neu in
uterine carcinosarcomas. The only previous study that
investigated HER-2/neu in this malignancy reported a
positive immunostaining in 9 of 16 cases, but did not
provide information on survival [33]. It is well known that
approximately 25% of breast cancers overexpress HER-2/
neu [38]. Anti-HER-2 (trastuzumab)-based combination
therapy is currently used for patients with metastatic breast
carcinoma that overexpress HER-2/neu and several studies
demonstrated a survival advantage [39]. Although we did
not found any prognostic role for HER-2/neu immunostain-
ing in our series, we could not exclude a beneficial effect of
trastuzumab in the treatment of recurrent or metastatic
carcinosarcomas with HER-2/neu overexpression. Recently,
a role for anti-HER-2 therapy has been hypothesized also in
5% of the patients with transitional cell carcinoma of the
urinary bladder, which overexpress HER-2/neu [40]. There-
fore, our results prompt further studies to clarify the issue of
possible clinical utility of anti-HER2 treatment in metastatic
uterine carcinosarcomas.
In conclusion, the most important outcome of the current
study was the observation, for the first time, of a prognostic
significance for COX-2 expression in uterine carcinosarco-
mas. The assessment of this biological tumor feature gave
by far more information on tumor aggressiveness than
classic histopathological parameters, such as presence of
heterologous component or depth of myometrial infiltration.
Hence, we believe that the relatively easy immunohisto-
chemical evaluation of COX-2 could improve the identi-
fication of patients with more aggressive disease and
possibly, candidate them to more individualized treatments.
Because this is the first report of the prognostic role of
COX-2 expression in uterine carcinosarcoma, our results
should be interpreted with caution and validated in a larger
series.
Another relevant outcome of this study was the
documentation of the expression of COX-2, c-KIT and
HER-2/neu in uterine carcinosarcomas, because we know
that these same gene products are molecular targets for
innovative treatments, such as COX-2 inhibitors, STI571
and trastuzumab, which had been already proven beneficial
in colorectal cancer, GIST and breast carcinoma,
respectively [16,41,42].
Indeed, our findings warrants further studies to verify if
these specific molecularly targeted treatments may have a
role in the treatment of uterine carcinosarcoma patients as
well.
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